New immune system understanding may lead to safer nanomedicinessay goodbye to drugs.

(Nanowerk News) Doctors would like to use all sorts of nanoparticles in the body, for example to construct detailed images of anatomy and disease, and to deliver cancer-fighting drugs deep within tumor tissue. However, millions of years of evolution have equipped the body to identify and reject foreign particles, even nanoparticles. And so one major challenge in the use of nanomedicine has been the immune system’s unfortunate efficiency in responding to what it sees as infection, at best clearing nanoparticles before they can accomplish their goals, and at worst, leading to dangerous immune overreaction that creates side effects and serious risks.

A University of Colorado Cancer Center study published in the journal Nature Nanotechnology(“Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles”) describes an important step in the activation of the immune system against nanoparticles. The finding may allow researchers and eventually doctors to cloak nanoparticles against the immune system, allowing these particles to go about their therapeutic business.
Dmitri Simberg
Dmitri Simberg
Previously, the lab of CU Cancer Center investigator Dmitri Simberg, PhD, has shown that blood proteins (collectively called protein corona) coat nanoparticles, marking them for immune system attack. In particular, the Simberg lab showed that one of the most important components of the immune system, namely the complement system, cannot attack nanoparticles unless they are coated with protein corona. Now the Simberg lab shows another step in this process: Natural antibodies within the protein corona are responsible for the ability of the complement system to recognize and attack nanoparticles.

“Basically, we found that C3 deposition on nanoparticles (and thus immune system activation against nanoparticles) really depends on natural antibodies in each person’s blood,” says Simberg, who is also an associate professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences. “We can remove these antibodies and there is very little complement system activation. Then we can add these antibodies back and there is activation.

The study, which was done in collaboration with Moein Moghimi, PhD, Professor at Newcastle University in the UK, looked at the ability of a prevalent complement system protein, known as C3, to find and attack widely used nanoparticle-based anti-cancer pharmaceuticals LipoDox and Onivyde, (as well as the nanoparticle-based iron oxide supplement Feraheme). When Simberg and colleagues depleted antibodies known as immunoglobulins from blood of healthy donors and cancer patients, the ability of C3 to find and mark these nanoparticles was reduced 70-95 percent. When the team restored immunoglobulins, they again saw C3 buildup on these nanomedicines.

“Our immunological memory is made up of antibodies that help us to recognize pathogens that we may have encountered long ago. Each person has a set of natural antibodies that recognizes nanoparticles. The individual reactivity of a person to a specific kind of nanoparticle depends to some extent on how much of these antibodies a person has. There’s variability – one person may have more antibodies that recognize a certain kind of nanoparticle, while another person has different antibodies that recognize another kind of nanoparticle,” says Simberg.
“What is really exciting is that all these antibodies seem not to bind to naked nanoparticles. The particle needs to be coated with a protein corona – binding of these antibodies is much more efficient when you have these other proteins sticking to the nanoparticles first,” Simberg says.
Continuing work hopes to discover the origin and source of antibodies that recognize nanoparticles, offering a clearer picture of why some people show immune over-response in reaction to nanoparticle-based medicines. By understanding how antibodies recognize nanoparticles, Simberg and his team hope to develop ways to selectively block this action, leading to more effect and less side effect of nanomedicines.

8th World Congress on Immunology

The University of Southampton said it had hit its fundraising goal six months early, raising money entirely through philanthropic donations.

Teams are set to start researching new treatments at the Centre for Cancer Immunology from March.

University vice chancellor Sir Christopher Snowden said the centre was “the first of its kind in the UK”.

A fundraising campaign for the four-storey building, based at Southampton General Hospital, started in 2015.

It will home 50 research staff and a specialist clinical trials unit,

Sir Chris said: “The next few years will see great advances in immunotherapies for cancer with the University of Southampton at the very forefront of discovery.”Copy of Welcome Card - Made with PosterMyWall (1)

8th World Congress on Immunology

copy of medical health centre flyer and brochure design template - made with postermywall



8th World Congress on Immunology
March 11-12, 2019, London, UK

Theme: Scrutinizing Recent Advancements in the Field of Immunology

Greetings from immunology world 2019!

peer-review publisher and conferences organizer established in the year 1984 publishes and hosts the work of researchers in a manner that exemplifies the highest standards in research integrity.
With a legacy of 30 years of excellence in Medical Publishing and with a support of various societies,

we are currently organizing, “8th World Congress on Immunology” scheduled during March 11-12, 2019 at London, UK with a theme of “Scrutinizing Recent Advancements in the Field of Immunology”. It is honour and privilege to invite your association members for the conference to participate for the Conference.

even with opportunity of being sponsors ,collaborators(show case your products at the conference) & media partners to our proud conference

I would like to briefly update you the Media Partner benefits: –
• Helping to increase your Membership through the participation of our respected associated scientists and researchers.
• Display logos on event paraphernalia and areas around the event space as required.
• Opportunity to showcase and demonstrate your services in our events.
• Discounts on suggested speakers/delegates.

Existing our mutual media partners are, Tabeeby, Vydya Health
Updated information about the event can be found in Conference Brochure
The Theme of the Conference will be on following topics:
• Immune system
• Immune response
• Immunity and infectious agents
• Antibodies
• Vaccinology
• Immunological assays
• Autoimmune disease
• Immunotherapy
• many more

NOTE: Each abstract will receive a Digital Object Identification Number (DOI) provided by CrossRef

NOTE: I request to bring this conference notice to all your associate members and student to be as speakers to our conference

Looking forward to your positive response
Please do not hesitate to contact us if we can be of further assistance.

copy of discount coupon - made with postermywall Pulsus Group invites all the participants from all over the world to attend “8th World Congress on Immunology” (Immunology World 2019) on March 11-12, 2019 at London, UK. The conference includes prompt keynote presentations, Workshops, Oral talks, Poster presentations and Exhibitions. Iranian Immunology Society Iranian Immunology Society hashtagimmunology hashtagbestconference #2019 hashtaglondon hashtaguk hashtagkeynote hashtagcongress hashtagconferences hashtagpresenter hashtagparticipative hashtagposterpresentations hashtagposterpresentations

Create a free website or blog at

Up ↑

Create your website at
Get started